MX2010004921A - Diaminas puenteadas o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa. - Google Patents
Diaminas puenteadas o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa.Info
- Publication number
- MX2010004921A MX2010004921A MX2010004921A MX2010004921A MX2010004921A MX 2010004921 A MX2010004921 A MX 2010004921A MX 2010004921 A MX2010004921 A MX 2010004921A MX 2010004921 A MX2010004921 A MX 2010004921A MX 2010004921 A MX2010004921 A MX 2010004921A
- Authority
- MX
- Mexico
- Prior art keywords
- leukotriene
- hydrolase
- aryl
- lta4h
- substituted bridged
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de diamina puenteados o fusionados sustituidos con arilo, composiciones farmacéuticas que los contienen y métodos de usar los compuestos y las composiciones farmacéuticas para la modulación de leucotrieno A4 hidrolasa (LTA4H o LTA4H) y para el tratamiento de los estados de enfermedad, trastornos y afecciones mediadas por la actividad de la LTA4H, tales como la alergia, asma, enfermedades autoinmunes, pruritis, enfermedad inflamatoria intestinal, colitis ulcerativa y enfermedad cardiovascular, incluso aterosclerosis y prevención del infarto del miocardio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98412607P | 2007-10-31 | 2007-10-31 | |
PCT/US2008/012339 WO2009058347A1 (en) | 2007-10-31 | 2008-10-31 | Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004921A true MX2010004921A (es) | 2010-05-27 |
Family
ID=40583652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004921A MX2010004921A (es) | 2007-10-31 | 2008-10-31 | Diaminas puenteadas o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa. |
Country Status (16)
Country | Link |
---|---|
US (3) | US7935725B2 (es) |
EP (1) | EP2217237A4 (es) |
JP (1) | JP5608088B2 (es) |
KR (1) | KR101573446B1 (es) |
CN (1) | CN101909628B (es) |
AR (1) | AR069126A1 (es) |
AU (1) | AU2008319266B2 (es) |
BR (1) | BRPI0818150A2 (es) |
CA (1) | CA2704320C (es) |
MX (1) | MX2010004921A (es) |
NZ (1) | NZ584881A (es) |
PA (1) | PA8802501A1 (es) |
PE (1) | PE20091017A1 (es) |
TW (1) | TW200932236A (es) |
UY (1) | UY31443A1 (es) |
WO (1) | WO2009058347A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935725B2 (en) | 2007-10-31 | 2011-05-03 | Janssen Pharmaceutica Nv | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase |
EP2268646B9 (en) * | 2008-04-11 | 2014-11-19 | Janssen Pharmaceutica, N.V. | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase |
KR101727650B1 (ko) * | 2009-05-14 | 2017-04-17 | 얀센 파마슈티카 엔.브이. | 류코트리엔 a4 하이드롤라아제의 조절제로서의 2개의 융합된 바이사이클릭 헤테로아릴 부분을 갖는 화합물 |
LT2861566T (lt) | 2012-06-13 | 2017-02-10 | F. Hoffmann-La Roche Ag | Nauji diazaspirocikloalkanai ir azaspirocikloalkanai |
CA2878442A1 (en) | 2012-09-25 | 2014-04-03 | F. Hoffmann-La Roche Ag | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
SI3074400T1 (en) | 2013-11-26 | 2018-03-30 | F. Hoffmann-La Roche Ag | Octahydro-cyclobut (1,2-c, 3,4-cy) dipyrrole derivatives as autoantaxine inhibitors |
UA118582C2 (uk) | 2014-03-26 | 2019-02-11 | Ф. Хоффманн-Ля Рош Аг | Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa) |
CN106029667B (zh) | 2014-03-26 | 2019-08-23 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物 |
EP3197886B1 (en) | 2014-09-26 | 2023-01-04 | Shifa Biomedical Corporation | Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
MX2020004504A (es) | 2015-09-04 | 2021-11-10 | Hoffmann La Roche | Derivados de fenoximetilo. |
BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
JP6846414B2 (ja) | 2015-09-24 | 2021-03-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Atx阻害剤としての二環式化合物 |
CA2991615A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
FR3063635B1 (fr) * | 2017-03-09 | 2019-06-07 | Pharmaleads | Derives aminophosphiniques pour la prevention et le traitement de l'inflammation oculaire |
CN110352060A (zh) * | 2017-03-09 | 2019-10-18 | 领先药物公司 | 用于预防和治疗眼部炎症的氨基次膦酸衍生物 |
CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
WO2018167001A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as dual atx/ca inhibitors |
CA3067062A1 (en) * | 2017-06-16 | 2018-12-20 | University Of Ottawa | Markers for disease and disease extent in inflammatory bowel disease |
WO2019057123A1 (zh) * | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
BR112021013637A2 (pt) | 2019-01-11 | 2021-09-14 | Naegis Pharmaceuticals Inc. | Inibidores da síntese de leucotrieno |
CN114466839A (zh) | 2019-05-31 | 2022-05-10 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
WO2021044351A1 (en) * | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
PE20231372A1 (es) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | Compuestos heterociclicos |
MX2023015436A (es) * | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ222047A (en) | 1986-10-08 | 1991-01-29 | Bristol Myers Co | Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents |
US5585492A (en) * | 1994-10-11 | 1996-12-17 | G. D. Searle & Co. | LTA4 Hydrolase inhibitors |
US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
EP0880363B1 (en) * | 1996-02-13 | 2002-09-11 | G.D. SEARLE & CO. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor |
US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
EP1367481A3 (en) * | 2002-05-29 | 2008-04-09 | Hitachi, Ltd. | Centralized storage management method |
AU2004247627A1 (en) | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
JP2007500703A (ja) * | 2003-07-28 | 2007-01-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびlta4hモジュレーターとしてのそれらの使用 |
US7435831B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
GB2415818B (en) | 2004-06-30 | 2008-12-31 | Autoliv Dev | Arrangement for triggering a vehicle safety device |
GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
US20070078263A1 (en) * | 2005-09-21 | 2007-04-05 | Decode Chemistry, Inc. | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation |
LT1976828T (lt) | 2005-12-29 | 2017-04-25 | Celtaxsys, Inc. | Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai |
US7935725B2 (en) | 2007-10-31 | 2011-05-03 | Janssen Pharmaceutica Nv | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase |
-
2008
- 2008-10-30 US US12/291,018 patent/US7935725B2/en not_active Expired - Fee Related
- 2008-10-30 TW TW097141714A patent/TW200932236A/zh unknown
- 2008-10-30 PE PE2008001861A patent/PE20091017A1/es not_active Application Discontinuation
- 2008-10-30 AR ARP080104759A patent/AR069126A1/es unknown
- 2008-10-30 UY UY31443A patent/UY31443A1/es unknown
- 2008-10-30 PA PA20088802501A patent/PA8802501A1/es unknown
- 2008-10-31 CA CA2704320A patent/CA2704320C/en not_active Expired - Fee Related
- 2008-10-31 MX MX2010004921A patent/MX2010004921A/es active IP Right Grant
- 2008-10-31 JP JP2010532059A patent/JP5608088B2/ja not_active Expired - Fee Related
- 2008-10-31 WO PCT/US2008/012339 patent/WO2009058347A1/en active Application Filing
- 2008-10-31 NZ NZ584881A patent/NZ584881A/xx not_active IP Right Cessation
- 2008-10-31 AU AU2008319266A patent/AU2008319266B2/en not_active Ceased
- 2008-10-31 EP EP08845395A patent/EP2217237A4/en not_active Withdrawn
- 2008-10-31 BR BRPI0818150 patent/BRPI0818150A2/pt not_active Application Discontinuation
- 2008-10-31 KR KR1020107011615A patent/KR101573446B1/ko active IP Right Grant
- 2008-10-31 CN CN2008801235416A patent/CN101909628B/zh not_active Expired - Fee Related
-
2011
- 2011-04-21 US US13/091,498 patent/US8344008B2/en active Active
- 2011-04-21 US US13/091,772 patent/US8367719B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
UY31443A1 (es) | 2009-04-30 |
EP2217237A4 (en) | 2011-08-17 |
CN101909628A (zh) | 2010-12-08 |
PA8802501A1 (es) | 2009-06-23 |
US8344008B2 (en) | 2013-01-01 |
TW200932236A (en) | 2009-08-01 |
EP2217237A1 (en) | 2010-08-18 |
JP5608088B2 (ja) | 2014-10-15 |
US7935725B2 (en) | 2011-05-03 |
JP2011502150A (ja) | 2011-01-20 |
US20090111794A1 (en) | 2009-04-30 |
CN101909628B (zh) | 2013-05-29 |
WO2009058347A1 (en) | 2009-05-07 |
KR101573446B1 (ko) | 2015-12-01 |
KR20100101582A (ko) | 2010-09-17 |
US20110257153A1 (en) | 2011-10-20 |
US8367719B2 (en) | 2013-02-05 |
CA2704320C (en) | 2017-01-03 |
AU2008319266B2 (en) | 2015-05-07 |
AU2008319266A1 (en) | 2009-05-07 |
PE20091017A1 (es) | 2009-07-16 |
CA2704320A1 (en) | 2009-05-07 |
US20110263639A1 (en) | 2011-10-27 |
NZ584881A (en) | 2012-08-31 |
AR069126A1 (es) | 2009-12-30 |
BRPI0818150A2 (pt) | 2015-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004921A (es) | Diaminas puenteadas o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa. | |
WO2011069063A3 (en) | Multicyclic compounds and methods of use thereof | |
WO2007089557A3 (en) | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators | |
HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
TW200738710A (en) | Tricyclic inhibitors of 5-lipoxygenase | |
EP2576540A4 (en) | HETEROARYLATED COMPOUNDS AND METHODS OF USE | |
MY151246A (en) | Benzofuranyl derivatives | |
WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
TW200740844A (en) | Novel MAdCAM antibodies | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
TW200801021A (en) | Imidazolothiazole compounds for the treatment of disease | |
TW200732296A (en) | Novel compounds | |
TN2011000382A1 (en) | Indole derivatives as crth2 receptor antagonists | |
TW200602330A (en) | Compounds and compositions as PPAR modulators | |
MX2010007392A (es) | Antagonistas de trpa1. | |
WO2007056366A3 (en) | Compounds and compositions as ppar modulators | |
PH12013500094A1 (en) | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase | |
JO2645B1 (en) | Vehicles | |
MX2008011175A (es) | Inhibidores de fosfodiesterasa 10. | |
MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
GB0611907D0 (en) | Compounds | |
GB0519760D0 (en) | Novel compounds | |
MX2011012190A (es) | Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa. | |
WO2008152094A3 (en) | Substituted acetamides as modulators of the ep2 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |